{"ticker": {"uuid": "c1afb69c-8a02-43b6-8e11-80d48708053d", "symbol": "AMPH", "name": "Amphastar P", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Dimensional Fund Advisors stake in Amphastar Pharmaceuticals (AMPH) hits 5.2%", "summary": "Dimensional Fund Advisors LP has reported a beneficial ownership of 2,305,107 shares of Amphastar Pharmaceuticals (AMPH) common stock, which represents 5.2% of the class as of June 30, 2026. The firm exercises sole voting power over 2,251,660 shares and sole dispositive power ove", "url": "https://www.stocktitan.net/sec-filings/AMPH/schedule-13g-amphastar-pharmaceuticals-inc-passive-investment-disclos-4ea9078f8d92.html", "source_name": "Stock Titan", "published_at": "2026-07-14T17:12:03", "published_display": "14 Jul 2026 17:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Amphastar P For: 13 July By Investing.com", "summary": "The article is a brief financial post from Investing.com, likely announcing a Form 4 filing for Amphastar Pharmaceuticals on July 13th. The content primarily consists of navigation links, advertisements, and market data, with very little substantive information about the Form 4 i", "url": "https://ca.investing.com/news/stock-market-news/form-4-amphastar-p-for-13-july-93CH-4732074", "source_name": "Investing.com Canada", "published_at": "2026-07-14T00:09:35", "published_display": "14 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals (AMPH) director reports initial insider ownership", "summary": "Amphastar Pharmaceuticals director Anthony T. Pierce has filed an initial insider ownership report (Form 3), indicating his status as a director but showing no equity or derivative holdings as of the report date. The filing reports zero buy, sell, or other transactions in Amphast", "url": "https://www.stocktitan.net/sec-filings/AMPH/form-3-amphastar-pharmaceuticals-inc-initial-statement-of-beneficial--cfb2082326df.html", "source_name": "Stock Titan", "published_at": "2026-07-13T23:09:35", "published_display": "13 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar (AMPH) director awarded 7,886 RSUs and 16,646 options at $19.02", "summary": "Amphastar Pharmaceuticals director Anthony T. Pierce was granted 7,886 restricted stock units (RSUs) and 16,646 stock options on July 9, 2026, as equity compensation. Both the RSUs and options will vest on July 9, 2027, with the options exercisable at $19.02 per share and expirin", "url": "https://www.stocktitan.net/sec-filings/AMPH/form-4-amphastar-pharmaceuticals-inc-insider-trading-activity-8baef104f504.html", "source_name": "Stock Titan", "published_at": "2026-07-13T23:09:35", "published_display": "13 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Amphastar Pharmaceuticals, Inc. Reports Material Event", "summary": "Amphastar Pharmaceuticals, Inc. announced an increase in its Board of Directors from ten to eleven members and appointed Anthony Pierce as a Class III director, effective July 9, 2026. Mr. Pierce will serve until the 2028 annual meeting and has been deemed independent by Nasdaq s", "url": "https://www.stocktitan.net/sec-filings/AMPH/8-k-amphastar-pharmaceuticals-inc-reports-material-event-098c975e8d86.html", "source_name": "Stock Titan", "published_at": "2026-07-13T09:41:14", "published_display": "13 Jul 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Amphastar Pharmaceuticals, Inc. \u2013 DUS:29A", "summary": "This article provides financial information for Amphastar Pharmaceuticals, Inc. (DUS:29A) on TradingView, focusing specifically on its enterprise value to EBITDA forward ratio. It indicates that the market was closed with no trades recorded at the time of publication. The content", "url": "https://www.tradingview.com/symbols/DUS-29A/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T00:39:23", "published_display": "10 Jul 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Unit Receives US FDA Warning Letter on Violations at California Facility", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/amphastar-unit-receives-us-fda-110418690.html", "source_name": "MT Newswires", "published_at": "2026-07-08T11:04:18+00:00", "published_display": "08 Jul 2026 11:04", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar stock slips on FDA warning letter (AMPH:NASDAQ)", "summary": "Amphastar Pharmaceuticals (AMPH) saw its stock decline after one of its subsidiaries, International Medication Systems, Limited, received a warning letter from the U.S. FDA. The warning letter cited manufacturing-related violations at a facility in California. This news led to a ", "url": "https://seekingalpha.com/news/4612201-amphastar-stock-slips-fda-warning-letter", "source_name": "Seeking Alpha", "published_at": "2026-07-08T11:39:50", "published_display": "08 Jul 2026 11:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Warning Letter targets Amphastar (NASDAQ: AMPH) IMS manufacturing facility", "summary": "Amphastar Pharmaceuticals (NASDAQ: AMPH) announced that its subsidiary, International Medication Systems (IMS), received an FDA Warning Letter on July 2, 2026, for its South El Monte, California manufacturing facility. The letter cites violations of Good Manufacturing Practice re", "url": "https://www.stocktitan.net/sec-filings/AMPH/8-k-amphastar-pharmaceuticals-inc-reports-material-event-f42ba365b53f.html", "source_name": "Stock Titan", "published_at": "2026-07-08T10:11:12", "published_display": "08 Jul 2026 10:11", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals subsidiary receives FDA warning letter over CGMP issues at California facility", "summary": "Amphastar Pharmaceuticals received an FDA Warning Letter for CGMP violations at its IMS South El Monte manufacturing facility on July 2, 2026, following a December 2025 inspection. The violations relate to investigation procedures, environmental monitoring, handling, and manufact", "url": "https://www.tradingview.com/news/tradingview:108e59fcbaaca:0-amphastar-pharmaceuticals-subsidiary-receives-fda-warning-letter-over-cgmp-issues-at-california-facility/", "source_name": "TradingView", "published_at": "2026-07-08T10:11:12", "published_display": "08 Jul 2026 10:11", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Amphastar Pharmaceuticals, Inc. \u2013 NASDAQ:AMPH", "summary": "The article focuses on the \"Price to earnings forward\" metric for Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) as displayed on TradingView. It provides a snapshot of this financial data point, indicating that the market is currently closed with no trades. The majority of the co", "url": "https://www.tradingview.com/symbols/NASDAQ-AMPH/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T14:12:56", "published_display": "05 Jul 2026 14:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Amphastar Pharmaceuticals, Inc. \u2013 DUS:29A", "summary": "This article provides financial information for Amphastar Pharmaceuticals, Inc. (DUS:29A) on the Dusseldorf Stock Exchange. It specifically highlights the company's price to earnings forward metric. The content largely consists of navigation and technical information related to T", "url": "https://www.tradingview.com/symbols/DUS-29A/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T01:10:06", "published_display": "05 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Amphastar Pharmaceuticals, Inc. \u2013 NASDAQ:AMPH", "summary": "This article focuses on the enterprise value to revenue forward metric for Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH). It appears to be a financial data snippet from TradingView, providing an overview of this specific financial ratio for the company. The content primarily dis", "url": "https://www.tradingview.com/symbols/NASDAQ-AMPH/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T08:41:03", "published_display": "01 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Amphastar Pharmaceuticals, Inc. \u2013 NASDAQ:AMPH", "summary": "This article identifies the enterprise value to EBIT forward for Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH). It is a finance-related piece from TradingView, which also provides additional market and financial data for the company. The article itself is a placeholder or title ", "url": "https://www.tradingview.com/symbols/NASDAQ-AMPH/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T20:10:00", "published_display": "29 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals, Inc. Stock 12\u2011Month Price Target Cut to $22, Implies 1% Upside", "summary": "Amphastar Pharmaceuticals, Inc. (AMPH) has seen its average 12-month price target cut from $22.83 to $22 by analysts, with a range of $19 to $30 per share. This new target implies a modest 1% potential upside from its June 26 closing price. The consensus rating among seven analys", "url": "https://www.tradingview.com/news/tradingview:73d0a7d60ef33:0-amphastar-pharmaceuticals-inc-stock-12-month-price-target-cut-to-22-implies-1-upside/", "source_name": "TradingView", "published_at": "2026-06-29T13:41:09", "published_display": "29 Jun 2026 13:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Update: BofA Securities Downgrades Amphastar Pharmaceuticals to Underperform From Neutral, Cuts Price Target to $20 From $25", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/bofa-securities-downgrades-amphastar-pharmaceuticals-120303847.html", "source_name": "MT Newswires", "published_at": "2026-06-29T12:03:03+00:00", "published_display": "29 Jun 2026 12:03", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals, Inc.(NasdaqGS: AMPH) added to Russell 2000 Dynamic Index", "summary": "Amphastar Pharmaceuticals, Inc. (NasdaqGS: AMPH) has been added to the Russell 2000 Dynamic Index, effective June 28, 2026. This news comes shortly after the company was dropped from several other Russell Growth benchmarks. The biopharmaceutical company focuses on developing and ", "url": "https://www.marketscreener.com/news/amphastar-pharmaceuticals-inc-nasdaqgs-amph-added-to-russell-2000-dynamic-index-ce7f5fdddb8df026", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T08:41:04", "published_display": "29 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Amphastar Pharmaceuticals, Inc. \u2013 NASDAQ:AMPH", "summary": "This article provides a brief snapshot of the \"Price to sales forward\" metric for Amphastar Pharmaceuticals, Inc. (AMPH) on the Nasdaq Stock Market. It indicates the stock market is closed with no trades. The main content focuses on navigation and related financial data services ", "url": "https://www.tradingview.com/symbols/NASDAQ-AMPH/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T08:38:57", "published_display": "29 Jun 2026 08:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA cuts Amphastar stock rating on limited growth visibility", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQaHZNdm9lNWwzNjVCZWtGcmk4dlBhUm9mb244TkVjSFk2ZGcwWWV6S2sySjNsQmQ3d1R0M1JwUkJjeS1UdzJhX08zbFVOYW5lZWlXZS13WGoxd1lfTXFrTTF0TW1UaHVDYmZneWFHWkljZXpFT0ZJZ1lxRld3dkR0Q19BbnI2VmpFM3VKYm5wNUdIX0c5VTJrTldTVEh6X1ZzcWhTMU5XWTR4cmZ3U2M3WGpKT1dhYXRTQnhJR0hn?oc=5", "source_name": "Investing.com", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Amphastar Pharmaceuticals, Inc. \u2013 LS:A11664", "summary": "This article focuses on the enterprise value to revenue forward metric for Amphastar Pharmaceuticals, Inc. (LS:A11664) as presented on TradingView. It appears to be a stub or data-focused page without detailed analysis, indicating that this financial metric is being tracked for t", "url": "https://www.tradingview.com/symbols/LS-A11664/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T03:40:19", "published_display": "29 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Amphastar Pharmaceuticals, Inc. \u2013 LS:A11664", "summary": "This article displays the \"Price to earnings forward\" metric for Amphastar Pharmaceuticals, Inc. (LS:A11664) from TradingView. The content indicates that the market is closed and no trades have occurred for this specific data point. It is presented within the context of financial", "url": "https://www.tradingview.com/symbols/LS-A11664/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T06:10:29", "published_display": "28 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMPH Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Amphastar Pharmaceuticals, Inc. (AMPH) stock, including analyst price targets, historical performance data, and financial metrics. It also addresses frequently asked questions about the company's stock, such as earnings reports, revenue, net i", "url": "https://www.tradingview.com/symbols/NASDAQ-AMPH/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T19:41:10", "published_display": "26 Jun 2026 19:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AMPH)", "summary": "This article provides an overview of Amphastar Pharmaceuticals, Inc. (AMPH) stock, including its current price, market capitalization, and historical performance. It details analyst forecasts with maximum and minimum price estimates, recent financial results, and future earnings ", "url": "https://www.tradingview.com/symbols/NASDAQ-AMPH/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T01:10:07", "published_display": "26 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals Inc (AMPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Amphastar Pharmaceuticals Inc (AMPH), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. The analysis indicates that AMPH's current price momentum score is 6.46, placin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-amph/technical", "source_name": "TradingKey", "published_at": "2026-06-22T16:41:13", "published_display": "22 Jun 2026 16:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMPH Technical Analysis & Stock Price Forecast", "summary": "This article provides a technical analysis and stock price forecast for Amphastar Pharmaceuticals, Inc (AMPH), indicating a \"Strong Sell\" consensus based on various technical indicators and moving averages. The analysis highlights that AMPH's share price is currently $18.81, trad", "url": "https://intellectia.ai/en/stock/AMPH/technical", "source_name": "Intellectia AI", "published_at": "2026-06-19T04:10:17", "published_display": "19 Jun 2026 04:10", "sentiment": "negative", "sentiment_pct": 26, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals Inc (AMPH) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides an analysis of Amphastar Pharmaceuticals Inc (AMPH)'s financial health, noting its stable financial status and high operating efficiency, with a current financial score of 8.76. The company's latest quarterly revenue increased by 0.38% year-over-year, and it", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-amph/financial-health", "source_name": "TradingKey", "published_at": "2026-06-19T03:40:25", "published_display": "19 Jun 2026 03:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals Inc (AMPH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Amphastar Pharmaceuticals Inc (AMPH) by business segment and geographical region. It highlights that \"Other products\" and \"BAQSIMI\" are the largest revenue contributors, while the United States accounts for the vast majority ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-amph/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T13:12:46", "published_display": "18 Jun 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals Inc (AMPH) Institutional Confidence", "summary": "Amphastar Pharmaceuticals Inc (AMPH) has an institutional shareholding score of 7.00, placing it 51st out of 157 in the Pharmaceuticals industry. The current institutional shareholding proportion is 79.72%, which is a 6.44% decrease quarter-over-quarter. James Simons is the large", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-amph/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T03:12:46", "published_display": "18 Jun 2026 03:12", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals Inc (AMPH) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Amphastar Pharmaceuticals Inc (AMPH) focusing on its dividend and stock split history. It notes that no dividends have been distributed by the company over the past five years and no stock split data is available. The page also presents curren", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-amph/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T20:39:39", "published_display": "17 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals Inc (AMPH) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Amphastar Pharmaceuticals Inc (AMPH) has an earnings forecast score of 6.00, ranking 132nd in the Pharmaceuticals industry. Analysts have set an average price target of $31.00 for AMPH, with a \"Hold\" rating based on 7 analysts. The company's expected revenue for the next quarter ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-amph/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T02:39:39", "published_display": "17 Jun 2026 02:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(AMPH) Price Dynamics and Execution-Aware Positioning", "summary": "This article provides an in-depth analysis of Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) stock, highlighting strong near and mid-term sentiment but a weak long-term outlook. It details three AI-generated trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014", "url": "https://news.stocktradersdaily.com/news_release/78/AMPH_Price_Dynamics_and_Execution-Aware_Positioning_061326054002_1781386802.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-13T17:40:00", "published_display": "13 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth", "summary": "", "url": "https://finance.yahoo.com/m/479f5292-3edc-322f-b33e-34b25d503c6c/amphastar-pharmaceuticals.html", "source_name": "MarketBeat", "published_at": "2026-06-10T23:08:11+00:00", "published_display": "10 Jun 2026 23:08", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMPH: Updated Outlook And Q1 Reset Will Support Future Upside Potential", "summary": "Amphastar Pharmaceuticals has seen its average analyst price target cut from $26.86 to $22.83 following recent Q1 results and a revised 2026 outlook. This adjustment reflects increased uncertainty regarding future revenue and margin projections, particularly concerning the potent", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-amph/amphastar-pharmaceuticals/jy2j9fxe-intensified-competition-will-erode-margins-for-generic-pharmaceuticals-rbwm/updates/13-amphastar-pharmaceuticals-analyst-price-targets-have-been-t", "source_name": "Simply Wall Street", "published_at": "2026-06-10T05:39:48", "published_display": "10 Jun 2026 05:39", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Investment Story For Amphastar Pharmaceuticals (AMPH) Is Evolving Without New Valuation Shifts", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/investment-story-amphastar-pharmaceuticals-amph-221742106.html", "source_name": "Simply Wall St.", "published_at": "2026-06-09T22:17:42+00:00", "published_display": "09 Jun 2026 22:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Lower Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQMkpXZWJTUGtvVVlRMVVUWTlWMllGUU16QnM2ZUx6TlktY0RJZ1dRVmN1YXlaNjA2ZG9lOGVKUURaMmxKR0puTmM2b2JSM09yRUpWM2lwYVpGNEM5WElyMm9hbmptTEdjaE9oZ3lHMktIenExbkhwUUVqMmhYQTdBUVMxQmFybnVqYXNwV18wODQ5dndGN19SQlNjY3N6SlI1b3dvUXc5M0g?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Roundup: Amphastar Pharmaceuticals (NASDAQ:AMPH) And The Rest Of The Pharmaceuticals Segment", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxNNWJOR1V0a0dBMW52X211VTlraVllTzFQRWIxRGpxU05VMFgtYmpheFctaHRUNXpoSE5MTV8tU2NCcEJJV0wyMGZ2bm5NZXk4bS1UdktSRGtOdk9lQmNqU1NPc2FWZjZnNjBta3F6U052SWFBX1p4TzNwcHkyS3BNcTVFM29HcFBlMFJHWjdNeWZiaUoxTGc3c3VnTVBhMzhYTXBtdURfeVRCNXVQYV93VFcwajgtbVJ5Y2k2R0dvSTlCbkxvQjM2UlpTT3FWQ19oekVtdHpJQnJQQm9kVExoU0M4QXBlLW1XUjh2TWNyaWc?oc=5", "source_name": "StockStory", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Amphastar Pharmaceuticals (AMPH) Narrative Is Shifting As Targets Fall And New Drugs Launch", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOTzJtOG1ZMko0UUg0d0N6XzJORHVLZjBUWFVWYk9fVjllcUEzWEIyaHJwN0dJZW85eTB1eVJaTVFkcG5oUDdKSTlYUUtPbUN4dGctYjB3R0VvTEE2dEtUU0dMMjVEc25lcEw2MmhqRGpfdUgwd1NCSURmc3g3ZzVDNWhkcGtBNHlNbVJBa3NMSXhtQmRpcDNTYkV3X2l3ZFRJX082RXFlWXBZVFdTX2FXeEhtYXVPRmVsNmc?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar May 2026 slides: pipeline shift masks near-term headwinds", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNY0ZOZ3V3TjJHWTd6dU0wV3pRUnZHenBxZjBMcmVQNXV5QjVQSEpwOUFjUGExVFRDY2VPM3JobUVFUjlWbnd2NVh4NnVQaTN4TzNhNGR2ZlpEcGNLc1pnM1RrZlN5b3NHZVpCNnh5U1RiRWl5RHRzY1lnbXg3UHFQc1pxYlFPbnNMcFhSd3lWZ28yb1B6QW1Ocl82dnpDMkswcV83QTV3MmpzODVRSUZ5dVhYX3l5cll3NmloREN6OA?oc=5", "source_name": "Investing.com", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPTldXZmxySjN6MlRhMmJ3U1lQUXhFVVZIY1NJYnpSblM1NWFaM0h2VG0xZmtFdkZnTHU4U1ltanpIUVlmWnVQOTBGTU8zbmdzSzdLc2hXU3dVS21YZEhfcm80TXM1OFp2YjlwLXJIbHZxMWdHMnU3a3JLUnpDSnBVU0ZkUnlDelpmSU1XX2hyeE9Hd1dLSVJkVkNDNjhFdlEyZXJFZGllcmVMVDNTc0Y3QQ?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar's CFO and regulatory chief speak May 13; webcast open", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOUm5LWk9yNjZrVTJHRl9BRlBtSXMtSFIwM0tXRjBGR0ZfT3hKdEJPYXFyZVAteFp5SGowMXBNdU4wWThtNXp1TzZZR0JUZWlhNGhwRXIxTS1aRVVkQkVmWEJTbldfT2t2eWdQRkd2c3o4TWNmcmV0R295cklPMHpMZXZnNUtoX0NBTjBNSHpRSTQyYjBfdEszZlgyNnpxQkFWdWJ3ZkdQbGRZQVp1bXlJTTlsNWoxa2RYTnA0?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies Downgrades Amphastar Pharmaceuticals (AMPH), Cites Lack of Meaningful Upside Catalysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQWlczOHN0QktmSUJiajlkdWxqTHBUNGpSVzhqRnQwWVRhNG40ekcySXg1d0ZIdS1mSDRZU1k5MWFrMmV6U2IwS2RKYUhuM2IzRmtKc0pNYm53eV84N0Fub1dlX0lTTWtaREthZFNvNXBHWGVuSjNPdzM2cURQcnFfcWpwRGpuRktxZV9KOVlVZ2Q4TnFZbS1LZzB6enhVWGVLODV0TEdwdHJ1RTNGY3EtQkZwcmpGbzg?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Amphastar Pharmaceuticals (AMPH) Shares Are Sliding Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOME5IWnoyenQ0eXpLMG5UREgxNVoyNjNwNmY4VzduME1ETEN5dFVqN2FUa21HYUc1MG13VWwxdUZpRFpCM1NWMnJZNUgtNnp3c3RvU1lOVEhRWW5PamtRWHJZY19IcXVrOGVLQmdOVi1SbWJzSWMtOEw1MUNVSGo1SW9tVUY2X3RKZThaRkdLV0xVaVg5dy14VXNiWWo4elp1Y2FXYlNPeEg4V3JGMUZr?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals (AMPH): Buy, Sell, or Hold Post Q4 Earnings?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPMXEtcUgySzJQUzExaGhRSDhra0Zwa09DTnRIWFF5Rk0xZ1FkWHl5MUpDLUxLb0xtMFRkN2hyR0xxMWxhUTRKaVRRX2s0eElaTGdMdWxNSE5XbzM4Qjh2RjVWYzdNTzJOQzdpekJhdlFza3hqR244M0dpVVpyVnVKRzFOWnJHSTViYTMyZnFLSy1Zak1UT2FTWFlONWVrZ0txVVE2OHdsZw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Amphastar Pharmaceuticals (AMPH) Shares Are Plunging Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQYWpFR0F4OFBmVFUzQVVubmlsbmwxVThJMFZENi14SzhHcVdYZXFYSUNnT1Q1alRTZGVtdEpsSm9CVGRxWTBIYnVuZW5JRWl5aERQcmcyMmI3ak5MS2RlUHdXa2Rfa2pYRVNDYWtYRzA5dENVcHdaR1dwMWhtYWZUSUJyOF9ncUF3UEV1eVBjTHY?oc=5", "source_name": "Market source", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Dimensional Fund Advisors stake in Amphastar Pharmaceuticals (AMPH) hits 5.2%", "summary": "Dimensional Fund Advisors LP has reported a beneficial ownership of 2,305,107 shares of Amphastar Pharmaceuticals (AMPH) common stock, which represents 5.2% of the class as of June 30, 2026. The firm exercises sole voting power over 2,251,660 shares and sole dispositive power ove", "url": "https://www.stocktitan.net/sec-filings/AMPH/schedule-13g-amphastar-pharmaceuticals-inc-passive-investment-disclos-4ea9078f8d92.html", "source_name": "Stock Titan", "published_at": "2026-07-14T17:12:03", "published_display": "14 Jul 2026 17:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Amphastar P For: 13 July By Investing.com", "summary": "The article is a brief financial post from Investing.com, likely announcing a Form 4 filing for Amphastar Pharmaceuticals on July 13th. The content primarily consists of navigation links, advertisements, and market data, with very little substantive information about the Form 4 i", "url": "https://ca.investing.com/news/stock-market-news/form-4-amphastar-p-for-13-july-93CH-4732074", "source_name": "Investing.com Canada", "published_at": "2026-07-14T00:09:35", "published_display": "14 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals (AMPH) director reports initial insider ownership", "summary": "Amphastar Pharmaceuticals director Anthony T. Pierce has filed an initial insider ownership report (Form 3), indicating his status as a director but showing no equity or derivative holdings as of the report date. The filing reports zero buy, sell, or other transactions in Amphast", "url": "https://www.stocktitan.net/sec-filings/AMPH/form-3-amphastar-pharmaceuticals-inc-initial-statement-of-beneficial--cfb2082326df.html", "source_name": "Stock Titan", "published_at": "2026-07-13T23:09:35", "published_display": "13 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar (AMPH) director awarded 7,886 RSUs and 16,646 options at $19.02", "summary": "Amphastar Pharmaceuticals director Anthony T. Pierce was granted 7,886 restricted stock units (RSUs) and 16,646 stock options on July 9, 2026, as equity compensation. Both the RSUs and options will vest on July 9, 2027, with the options exercisable at $19.02 per share and expirin", "url": "https://www.stocktitan.net/sec-filings/AMPH/form-4-amphastar-pharmaceuticals-inc-insider-trading-activity-8baef104f504.html", "source_name": "Stock Titan", "published_at": "2026-07-13T23:09:35", "published_display": "13 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Amphastar Pharmaceuticals, Inc. Reports Material Event", "summary": "Amphastar Pharmaceuticals, Inc. announced an increase in its Board of Directors from ten to eleven members and appointed Anthony Pierce as a Class III director, effective July 9, 2026. Mr. Pierce will serve until the 2028 annual meeting and has been deemed independent by Nasdaq s", "url": "https://www.stocktitan.net/sec-filings/AMPH/8-k-amphastar-pharmaceuticals-inc-reports-material-event-098c975e8d86.html", "source_name": "Stock Titan", "published_at": "2026-07-13T09:41:14", "published_display": "13 Jul 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Amphastar Pharmaceuticals, Inc. \u2013 DUS:29A", "summary": "This article provides financial information for Amphastar Pharmaceuticals, Inc. (DUS:29A) on TradingView, focusing specifically on its enterprise value to EBITDA forward ratio. It indicates that the market was closed with no trades recorded at the time of publication. The content", "url": "https://www.tradingview.com/symbols/DUS-29A/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T00:39:23", "published_display": "10 Jul 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Unit Receives US FDA Warning Letter on Violations at California Facility", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/amphastar-unit-receives-us-fda-110418690.html", "source_name": "MT Newswires", "published_at": "2026-07-08T11:04:18+00:00", "published_display": "08 Jul 2026 11:04", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar stock slips on FDA warning letter (AMPH:NASDAQ)", "summary": "Amphastar Pharmaceuticals (AMPH) saw its stock decline after one of its subsidiaries, International Medication Systems, Limited, received a warning letter from the U.S. FDA. The warning letter cited manufacturing-related violations at a facility in California. This news led to a ", "url": "https://seekingalpha.com/news/4612201-amphastar-stock-slips-fda-warning-letter", "source_name": "Seeking Alpha", "published_at": "2026-07-08T11:39:50", "published_display": "08 Jul 2026 11:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Warning Letter targets Amphastar (NASDAQ: AMPH) IMS manufacturing facility", "summary": "Amphastar Pharmaceuticals (NASDAQ: AMPH) announced that its subsidiary, International Medication Systems (IMS), received an FDA Warning Letter on July 2, 2026, for its South El Monte, California manufacturing facility. The letter cites violations of Good Manufacturing Practice re", "url": "https://www.stocktitan.net/sec-filings/AMPH/8-k-amphastar-pharmaceuticals-inc-reports-material-event-f42ba365b53f.html", "source_name": "Stock Titan", "published_at": "2026-07-08T10:11:12", "published_display": "08 Jul 2026 10:11", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals subsidiary receives FDA warning letter over CGMP issues at California facility", "summary": "Amphastar Pharmaceuticals received an FDA Warning Letter for CGMP violations at its IMS South El Monte manufacturing facility on July 2, 2026, following a December 2025 inspection. The violations relate to investigation procedures, environmental monitoring, handling, and manufact", "url": "https://www.tradingview.com/news/tradingview:108e59fcbaaca:0-amphastar-pharmaceuticals-subsidiary-receives-fda-warning-letter-over-cgmp-issues-at-california-facility/", "source_name": "TradingView", "published_at": "2026-07-08T10:11:12", "published_display": "08 Jul 2026 10:11", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Amphastar Pharmaceuticals, Inc. \u2013 NASDAQ:AMPH", "summary": "The article focuses on the \"Price to earnings forward\" metric for Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) as displayed on TradingView. It provides a snapshot of this financial data point, indicating that the market is currently closed with no trades. The majority of the co", "url": "https://www.tradingview.com/symbols/NASDAQ-AMPH/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T14:12:56", "published_display": "05 Jul 2026 14:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Amphastar Pharmaceuticals, Inc. \u2013 DUS:29A", "summary": "This article provides financial information for Amphastar Pharmaceuticals, Inc. (DUS:29A) on the Dusseldorf Stock Exchange. It specifically highlights the company's price to earnings forward metric. The content largely consists of navigation and technical information related to T", "url": "https://www.tradingview.com/symbols/DUS-29A/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T01:10:06", "published_display": "05 Jul 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Amphastar Pharmaceuticals, Inc. \u2013 NASDAQ:AMPH", "summary": "This article focuses on the enterprise value to revenue forward metric for Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH). It appears to be a financial data snippet from TradingView, providing an overview of this specific financial ratio for the company. The content primarily dis", "url": "https://www.tradingview.com/symbols/NASDAQ-AMPH/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T08:41:03", "published_display": "01 Jul 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Amphastar Pharmaceuticals, Inc. \u2013 NASDAQ:AMPH", "summary": "This article identifies the enterprise value to EBIT forward for Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH). It is a finance-related piece from TradingView, which also provides additional market and financial data for the company. The article itself is a placeholder or title ", "url": "https://www.tradingview.com/symbols/NASDAQ-AMPH/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T20:10:00", "published_display": "29 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals, Inc. Stock 12\u2011Month Price Target Cut to $22, Implies 1% Upside", "summary": "Amphastar Pharmaceuticals, Inc. (AMPH) has seen its average 12-month price target cut from $22.83 to $22 by analysts, with a range of $19 to $30 per share. This new target implies a modest 1% potential upside from its June 26 closing price. The consensus rating among seven analys", "url": "https://www.tradingview.com/news/tradingview:73d0a7d60ef33:0-amphastar-pharmaceuticals-inc-stock-12-month-price-target-cut-to-22-implies-1-upside/", "source_name": "TradingView", "published_at": "2026-06-29T13:41:09", "published_display": "29 Jun 2026 13:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Update: BofA Securities Downgrades Amphastar Pharmaceuticals to Underperform From Neutral, Cuts Price Target to $20 From $25", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/bofa-securities-downgrades-amphastar-pharmaceuticals-120303847.html", "source_name": "MT Newswires", "published_at": "2026-06-29T12:03:03+00:00", "published_display": "29 Jun 2026 12:03", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals, Inc.(NasdaqGS: AMPH) added to Russell 2000 Dynamic Index", "summary": "Amphastar Pharmaceuticals, Inc. (NasdaqGS: AMPH) has been added to the Russell 2000 Dynamic Index, effective June 28, 2026. This news comes shortly after the company was dropped from several other Russell Growth benchmarks. The biopharmaceutical company focuses on developing and ", "url": "https://www.marketscreener.com/news/amphastar-pharmaceuticals-inc-nasdaqgs-amph-added-to-russell-2000-dynamic-index-ce7f5fdddb8df026", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T08:41:04", "published_display": "29 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Amphastar Pharmaceuticals, Inc. \u2013 NASDAQ:AMPH", "summary": "This article provides a brief snapshot of the \"Price to sales forward\" metric for Amphastar Pharmaceuticals, Inc. (AMPH) on the Nasdaq Stock Market. It indicates the stock market is closed with no trades. The main content focuses on navigation and related financial data services ", "url": "https://www.tradingview.com/symbols/NASDAQ-AMPH/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T08:38:57", "published_display": "29 Jun 2026 08:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA cuts Amphastar stock rating on limited growth visibility", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQaHZNdm9lNWwzNjVCZWtGcmk4dlBhUm9mb244TkVjSFk2ZGcwWWV6S2sySjNsQmQ3d1R0M1JwUkJjeS1UdzJhX08zbFVOYW5lZWlXZS13WGoxd1lfTXFrTTF0TW1UaHVDYmZneWFHWkljZXpFT0ZJZ1lxRld3dkR0Q19BbnI2VmpFM3VKYm5wNUdIX0c5VTJrTldTVEh6X1ZzcWhTMU5XWTR4cmZ3U2M3WGpKT1dhYXRTQnhJR0hn?oc=5", "source_name": "Investing.com", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Amphastar Pharmaceuticals, Inc. \u2013 LS:A11664", "summary": "This article focuses on the enterprise value to revenue forward metric for Amphastar Pharmaceuticals, Inc. (LS:A11664) as presented on TradingView. It appears to be a stub or data-focused page without detailed analysis, indicating that this financial metric is being tracked for t", "url": "https://www.tradingview.com/symbols/LS-A11664/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T03:40:19", "published_display": "29 Jun 2026 03:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Amphastar Pharmaceuticals, Inc. \u2013 LS:A11664", "summary": "This article displays the \"Price to earnings forward\" metric for Amphastar Pharmaceuticals, Inc. (LS:A11664) from TradingView. The content indicates that the market is closed and no trades have occurred for this specific data point. It is presented within the context of financial", "url": "https://www.tradingview.com/symbols/LS-A11664/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T06:10:29", "published_display": "28 Jun 2026 06:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMPH Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Amphastar Pharmaceuticals, Inc. (AMPH) stock, including analyst price targets, historical performance data, and financial metrics. It also addresses frequently asked questions about the company's stock, such as earnings reports, revenue, net i", "url": "https://www.tradingview.com/symbols/NASDAQ-AMPH/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T19:41:10", "published_display": "26 Jun 2026 19:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AMPH)", "summary": "This article provides an overview of Amphastar Pharmaceuticals, Inc. (AMPH) stock, including its current price, market capitalization, and historical performance. It details analyst forecasts with maximum and minimum price estimates, recent financial results, and future earnings ", "url": "https://www.tradingview.com/symbols/NASDAQ-AMPH/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T01:10:07", "published_display": "26 Jun 2026 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals Inc (AMPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Amphastar Pharmaceuticals Inc (AMPH), focusing on its price momentum, support and resistance levels, and various technical indicators and moving averages. The analysis indicates that AMPH's current price momentum score is 6.46, placin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-amph/technical", "source_name": "TradingKey", "published_at": "2026-06-22T16:41:13", "published_display": "22 Jun 2026 16:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMPH Technical Analysis & Stock Price Forecast", "summary": "This article provides a technical analysis and stock price forecast for Amphastar Pharmaceuticals, Inc (AMPH), indicating a \"Strong Sell\" consensus based on various technical indicators and moving averages. The analysis highlights that AMPH's share price is currently $18.81, trad", "url": "https://intellectia.ai/en/stock/AMPH/technical", "source_name": "Intellectia AI", "published_at": "2026-06-19T04:10:17", "published_display": "19 Jun 2026 04:10", "sentiment": "negative", "sentiment_pct": 26, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals Inc (AMPH) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides an analysis of Amphastar Pharmaceuticals Inc (AMPH)'s financial health, noting its stable financial status and high operating efficiency, with a current financial score of 8.76. The company's latest quarterly revenue increased by 0.38% year-over-year, and it", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-amph/financial-health", "source_name": "TradingKey", "published_at": "2026-06-19T03:40:25", "published_display": "19 Jun 2026 03:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals Inc (AMPH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Amphastar Pharmaceuticals Inc (AMPH) by business segment and geographical region. It highlights that \"Other products\" and \"BAQSIMI\" are the largest revenue contributors, while the United States accounts for the vast majority ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-amph/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T13:12:46", "published_display": "18 Jun 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals Inc (AMPH) Institutional Confidence", "summary": "Amphastar Pharmaceuticals Inc (AMPH) has an institutional shareholding score of 7.00, placing it 51st out of 157 in the Pharmaceuticals industry. The current institutional shareholding proportion is 79.72%, which is a 6.44% decrease quarter-over-quarter. James Simons is the large", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-amph/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T03:12:46", "published_display": "18 Jun 2026 03:12", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals Inc (AMPH) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Amphastar Pharmaceuticals Inc (AMPH) focusing on its dividend and stock split history. It notes that no dividends have been distributed by the company over the past five years and no stock split data is available. The page also presents curren", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-amph/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T20:39:39", "published_display": "17 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals Inc (AMPH) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Amphastar Pharmaceuticals Inc (AMPH) has an earnings forecast score of 6.00, ranking 132nd in the Pharmaceuticals industry. Analysts have set an average price target of $31.00 for AMPH, with a \"Hold\" rating based on 7 analysts. The company's expected revenue for the next quarter ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-amph/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T02:39:39", "published_display": "17 Jun 2026 02:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(AMPH) Price Dynamics and Execution-Aware Positioning", "summary": "This article provides an in-depth analysis of Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) stock, highlighting strong near and mid-term sentiment but a weak long-term outlook. It details three AI-generated trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014", "url": "https://news.stocktradersdaily.com/news_release/78/AMPH_Price_Dynamics_and_Execution-Aware_Positioning_061326054002_1781386802.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-13T17:40:00", "published_display": "13 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth", "summary": "", "url": "https://finance.yahoo.com/m/479f5292-3edc-322f-b33e-34b25d503c6c/amphastar-pharmaceuticals.html", "source_name": "MarketBeat", "published_at": "2026-06-10T23:08:11+00:00", "published_display": "10 Jun 2026 23:08", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AMPH: Updated Outlook And Q1 Reset Will Support Future Upside Potential", "summary": "Amphastar Pharmaceuticals has seen its average analyst price target cut from $26.86 to $22.83 following recent Q1 results and a revised 2026 outlook. This adjustment reflects increased uncertainty regarding future revenue and margin projections, particularly concerning the potent", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-amph/amphastar-pharmaceuticals/jy2j9fxe-intensified-competition-will-erode-margins-for-generic-pharmaceuticals-rbwm/updates/13-amphastar-pharmaceuticals-analyst-price-targets-have-been-t", "source_name": "Simply Wall Street", "published_at": "2026-06-10T05:39:48", "published_display": "10 Jun 2026 05:39", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Investment Story For Amphastar Pharmaceuticals (AMPH) Is Evolving Without New Valuation Shifts", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/investment-story-amphastar-pharmaceuticals-amph-221742106.html", "source_name": "Simply Wall St.", "published_at": "2026-06-09T22:17:42+00:00", "published_display": "09 Jun 2026 22:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Lower Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQMkpXZWJTUGtvVVlRMVVUWTlWMllGUU16QnM2ZUx6TlktY0RJZ1dRVmN1YXlaNjA2ZG9lOGVKUURaMmxKR0puTmM2b2JSM09yRUpWM2lwYVpGNEM5WElyMm9hbmptTEdjaE9oZ3lHMktIenExbkhwUUVqMmhYQTdBUVMxQmFybnVqYXNwV18wODQ5dndGN19SQlNjY3N6SlI1b3dvUXc5M0g?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Roundup: Amphastar Pharmaceuticals (NASDAQ:AMPH) And The Rest Of The Pharmaceuticals Segment", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxNNWJOR1V0a0dBMW52X211VTlraVllTzFQRWIxRGpxU05VMFgtYmpheFctaHRUNXpoSE5MTV8tU2NCcEJJV0wyMGZ2bm5NZXk4bS1UdktSRGtOdk9lQmNqU1NPc2FWZjZnNjBta3F6U052SWFBX1p4TzNwcHkyS3BNcTVFM29HcFBlMFJHWjdNeWZiaUoxTGc3c3VnTVBhMzhYTXBtdURfeVRCNXVQYV93VFcwajgtbVJ5Y2k2R0dvSTlCbkxvQjM2UlpTT3FWQ19oekVtdHpJQnJQQm9kVExoU0M4QXBlLW1XUjh2TWNyaWc?oc=5", "source_name": "StockStory", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Amphastar Pharmaceuticals (AMPH) Narrative Is Shifting As Targets Fall And New Drugs Launch", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOTzJtOG1ZMko0UUg0d0N6XzJORHVLZjBUWFVWYk9fVjllcUEzWEIyaHJwN0dJZW85eTB1eVJaTVFkcG5oUDdKSTlYUUtPbUN4dGctYjB3R0VvTEE2dEtUU0dMMjVEc25lcEw2MmhqRGpfdUgwd1NCSURmc3g3ZzVDNWhkcGtBNHlNbVJBa3NMSXhtQmRpcDNTYkV3X2l3ZFRJX082RXFlWXBZVFdTX2FXeEhtYXVPRmVsNmc?oc=5", "source_name": "Market source", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar May 2026 slides: pipeline shift masks near-term headwinds", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNY0ZOZ3V3TjJHWTd6dU0wV3pRUnZHenBxZjBMcmVQNXV5QjVQSEpwOUFjUGExVFRDY2VPM3JobUVFUjlWbnd2NVh4NnVQaTN4TzNhNGR2ZlpEcGNLc1pnM1RrZlN5b3NHZVpCNnh5U1RiRWl5RHRzY1lnbXg3UHFQc1pxYlFPbnNMcFhSd3lWZ28yb1B6QW1Ocl82dnpDMkswcV83QTV3MmpzODVRSUZ5dVhYX3l5cll3NmloREN6OA?oc=5", "source_name": "Investing.com", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPTldXZmxySjN6MlRhMmJ3U1lQUXhFVVZIY1NJYnpSblM1NWFaM0h2VG0xZmtFdkZnTHU4U1ltanpIUVlmWnVQOTBGTU8zbmdzSzdLc2hXU3dVS21YZEhfcm80TXM1OFp2YjlwLXJIbHZxMWdHMnU3a3JLUnpDSnBVU0ZkUnlDelpmSU1XX2hyeE9Hd1dLSVJkVkNDNjhFdlEyZXJFZGllcmVMVDNTc0Y3QQ?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar's CFO and regulatory chief speak May 13; webcast open", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOUm5LWk9yNjZrVTJHRl9BRlBtSXMtSFIwM0tXRjBGR0ZfT3hKdEJPYXFyZVAteFp5SGowMXBNdU4wWThtNXp1TzZZR0JUZWlhNGhwRXIxTS1aRVVkQkVmWEJTbldfT2t2eWdQRkd2c3o4TWNmcmV0R295cklPMHpMZXZnNUtoX0NBTjBNSHpRSTQyYjBfdEszZlgyNnpxQkFWdWJ3ZkdQbGRZQVp1bXlJTTlsNWoxa2RYTnA0?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies Downgrades Amphastar Pharmaceuticals (AMPH), Cites Lack of Meaningful Upside Catalysts", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQWlczOHN0QktmSUJiajlkdWxqTHBUNGpSVzhqRnQwWVRhNG40ekcySXg1d0ZIdS1mSDRZU1k5MWFrMmV6U2IwS2RKYUhuM2IzRmtKc0pNYm53eV84N0Fub1dlX0lTTWtaREthZFNvNXBHWGVuSjNPdzM2cURQcnFfcWpwRGpuRktxZV9KOVlVZ2Q4TnFZbS1LZzB6enhVWGVLODV0TEdwdHJ1RTNGY3EtQkZwcmpGbzg?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Amphastar Pharmaceuticals (AMPH) Shares Are Sliding Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOME5IWnoyenQ0eXpLMG5UREgxNVoyNjNwNmY4VzduME1ETEN5dFVqN2FUa21HYUc1MG13VWwxdUZpRFpCM1NWMnJZNUgtNnp3c3RvU1lOVEhRWW5PamtRWHJZY19IcXVrOGVLQmdOVi1SbWJzSWMtOEw1MUNVSGo1SW9tVUY2X3RKZThaRkdLV0xVaVg5dy14VXNiWWo4elp1Y2FXYlNPeEg4V3JGMUZr?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amphastar Pharmaceuticals (AMPH): Buy, Sell, or Hold Post Q4 Earnings?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPMXEtcUgySzJQUzExaGhRSDhra0Zwa09DTnRIWFF5Rk0xZ1FkWHl5MUpDLUxLb0xtMFRkN2hyR0xxMWxhUTRKaVRRX2s0eElaTGdMdWxNSE5XbzM4Qjh2RjVWYzdNTzJOQzdpekJhdlFza3hqR244M0dpVVpyVnVKRzFOWnJHSTViYTMyZnFLSy1Zak1UT2FTWFlONWVrZ0txVVE2OHdsZw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Amphastar Pharmaceuticals (AMPH) Shares Are Plunging Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQYWpFR0F4OFBmVFUzQVVubmlsbmwxVThJMFZENi14SzhHcVdYZXFYSUNnT1Q1alRTZGVtdEpsSm9CVGRxWTBIYnVuZW5JRWl5aERQcmcyMmI3ak5MS2RlUHdXa2Rfa2pYRVNDYWtYRzA5dENVcHdaR1dwMWhtYWZUSUJyOF9ncUF3UEV1eVBjTHY?oc=5", "source_name": "Market source", "published_at": "2026-02-27T08:00:00+00:00", "published_display": "27 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 78, "total_relevant": 44, "sentiment_summary": {"positive": 5, "negative": 12, "neutral": 27, "score": 47, "total": 44, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 11.9, "count": 21}, {"event": "earnings", "label": "Earnings", "weight": 7.15, "count": 13}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 5, "negative_events": 12}, "market_context": {"has_market_context": true, "latest_close": 18.72, "latest_week": "2026-07-10", "one_week_move": -4.7, "four_week_move": -6.8, "twelve_week_move": -18.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.292701, "market_dynamics_buy_signal": false, "relative_strength": -33.216191, "fair_value_gap": -48.5, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 49.2838, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.7% over one week, -6.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 12}, {"label": "Market source", "count": 7}, {"label": "Stock Titan", "count": 6}, {"label": "TradingKey", "count": 6}, {"label": "MT Newswires", "count": 2}, {"label": "Investing.com", "count": 2}, {"label": "Investing.com Canada", "count": 1}, {"label": "Seeking Alpha", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 44}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 21}, {"label": "Earnings", "count": 13}, {"label": "Analyst action", "count": 4}, {"label": "Regulatory and legal", "count": 2}, {"label": "Guidance", "count": 2}, {"label": "Deals and strategy", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "47/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "44", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-4.7% over one week, -6.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Dimensional Fund Advisors stake in Amphastar Pharmaceuticals (AMPH) hits 5.2%"}], "updated_at": "2026-07-16T00:45:51.972376+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}